| Trial ID: | L4965 |
| Source ID: | NCT06706284
|
| Associated Drug: |
Semaglutide Injectable Product
|
| Title: |
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Spinal Cord Injuries|Type 2 Diabetes
|
| Interventions: |
DRUG: Semaglutide Injectable Product|OTHER: Placebo
|
| Outcome Measures: |
Primary: Glucose tolerance, Alteration in prandial glucose concentrations using meal studies, Baseline to 24 weeks|Insulin sensitivity, Change in insulin sensitivity using euglycemic clamp, Baseline to 24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Marzieh Salehi | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2025-03-25
|
| Completion Date: |
2029-01-01
|
| Results First Posted: |
|
| Last Update Posted: |
2025-03-18
|
| Locations: |
University Health - Texas Diabetic Institute, San Antonio, Texas, 78207, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT06706284
|
